What Does Xarelto Cost in 2026? IRA Price, Generic Status, and All Savings Options

Xarelto (rivaroxaban) is a direct oral anticoagulant (DOAC) prescribed to reduce the risk of stroke and blood clots in patients with atrial fibrillation (AFib), and to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used to reduce the risk of major cardiovascular events in patients with coronary artery disease or peripheral artery disease. Xarelto is manufactured by Janssen Pharmaceuticals (a Johnson and Johnson subsidiary) and co-developed with Bayer. It has been one of the highest-revenue anticoagulants globally, with US annual sales exceeding $8 billion before generic entry.

The Inflation Reduction Act of 2022, signed on August 16, 2022, authorized CMS to directly negotiate drug prices with manufacturers for the first time in Medicare's history. Xarelto was selected as one of the first 10 drugs for Round 1 negotiations. The negotiated Maximum Fair Price of $197 per month took effect January 1, 2026, a 62% reduction from the $517 list price. Eliquis, the other top anticoagulant DOAC, received a negotiated price of $231 per month under the same program. CMS has since announced Xarelto will be removed from the negotiated list effective January 1, 2027, because at least one approved generic is now being marketed. For 2026, the $197 MFP applies at all network pharmacies for Medicare Part D enrollees.

The generic landscape for rivaroxaban is evolving rapidly. The FDA approved the first generic rivaroxaban 2.5mg tablets in March 2025, and Lupin launched them commercially within weeks. In May 2025, Lupin received FDA approval for 10mg, 15mg, and 20mg generic rivaroxaban, the doses used by the vast majority of patients. Commercial availability for the higher-strength generics is still expanding into the broader market as of mid-2026, with secondary patents potentially affecting some formulations through 2034. Patients taking 2.5mg can now access generic rivaroxaban at roughly $45 per month through GoodRx, representing a 90% savings versus retail brand. Patients on 10mg to 20mg should check with their pharmacy directly for current generic availability. Medicare beneficiaries who qualify for Extra Help pay a reduced flat copay regardless of which formulary tier Xarelto is placed on. Low-income patients should also review Medicaid income limits to see if they qualify for near-zero cost coverage.

What Xarelto Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same xarelto can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

When you are admitted to the hospital and receive Xarelto as part of your inpatient care, the cost is almost never billed as a separate pharmacy line item at the retail price. Under Medicare Part A, the cost of oral anticoagulants like rivaroxaban is bundled into the Diagnosis-Related Group (DRG) payment for your hospital stay. The DRG is a flat fee Medicare pays the hospital based on your diagnosis, not the actual cost of individual drugs. Private insurers negotiate their own bundled rates. Patients without insurance face the hospital's chargemaster rate, which can be 2 to 3 times the Medicare equivalent.

For patients managing AFib or DVT long-term, the real cost exposure is in the outpatient pharmacy setting, not the hospital. Once discharged, Xarelto falls under Medicare Part D rather than Part A. That is where the IRA-negotiated $197 per month Maximum Fair Price applies for 2026. Patients who transition from inpatient to outpatient care without an active Part D plan can face the full retail price of $517 to $805 per month until they enroll. Patients discharged without Part D coverage should contact 1-800-MEDICARE immediately to review enrollment options, as certain qualifying events allow for a Special Enrollment Period.

The emergence of generic rivaroxaban changes the long-term cost picture significantly. When multiple generic manufacturers fully distribute the 10mg, 15mg, and 20mg strengths, retail pharmacy prices are expected to fall 70 to 90 percent from current brand levels, as typically occurs with generic market maturation. The 2.5mg generic already demonstrates this: a dose that cost $517 per month at brand price is available for about $45 per month as a generic. Patients on 10mg to 20mg should monitor their pharmacy's generic availability and ask their prescriber and pharmacist whether a generic substitution is appropriate.

Patient Assistance Programs

Janssen Pharmaceuticals (J and J) operates two main assistance pathways for Xarelto patients. The XARELTO withMe savings card covers commercially insured patients, reducing out-of-pocket cost to as little as $10 per fill. The Janssen CarePath Patient Assistance Program provides free Xarelto to uninsured or underinsured patients who meet income requirements. IMPORTANT: If you have Medicare, Medicaid, TRICARE, or VA coverage, federal anti-kickback statute (42 U.S.C. Section 1320a-7b) prohibits using manufacturer copay coupons. Medicare Part D patients use the IRA-negotiated $197 Maximum Fair Price instead. Medicare patients who cannot afford $197 per month should apply for Part D Extra Help through Social Security at 1-800-772-1213.

Medicare Part D

Xarelto is a Part D drug, meaning Medicare covers it through Part D prescription drug plans rather than Part B. In 2026, Medicare Part D enrollees pay the IRA-negotiated Maximum Fair Price of $197 per month for Xarelto. This is the maximum you pay at any network pharmacy; your actual copay may be lower depending on your plan's tier structure. All Xarelto spending counts toward the 2026 annual Part D out-of-pocket cap of $2,100. Once you reach $2,100 in out-of-pocket spending during the year, your Part D plan covers 100% of remaining drug costs for the rest of the calendar year.

Note: CMS has announced that Xarelto will be removed from the IRA negotiated drugs list effective January 1, 2027, because at least one approved generic version is now being marketed in the US. For 2027 and beyond, the price patients pay will depend on their plan's formulary tier and the market availability of generic rivaroxaban. Patients who are currently benefiting from the $197 MFP should monitor their Part D plan's 2027 formulary during annual open enrollment (October 15 to December 7, 2026) to understand what their cost will be in 2027.

Common Xarelto Billing Errors

Xarelto is an oral self-administered medication billed primarily through Part D (not Part B), so most billing issues occur at the pharmacy or on Explanation of Benefits statements rather than on hospital itemized bills. Common errors include:

• Pharmacy charges more than $197 per month for Medicare Part D patients in 2026, which violates the IRA Maximum Fair Price requirement; call your plan's member services immediately
• Inpatient hospital bill lists rivaroxaban as a separate drug charge when the cost should be bundled into the DRG payment; this is a common billing error for oral anticoagulants administered during an inpatient stay
• Brand-name Xarelto dispensed when a generic rivaroxaban equivalent was available and would have lowered the patient's cost (formulary substitution opportunity not flagged)
• XARELTO withMe savings card applied to a Medicare or Medicaid claim in violation of the anti-kickback statute, resulting in claim rejection that delays fill and creates apparent overcharge
• Incorrect strength dispensed (10mg vs 15mg vs 20mg) and billed at the wrong price; confirm the dispensed strength matches the prescription and the price matches the correct strength's formulary tier
• Failure to apply Part D Extra Help (Low Income Subsidy) copay reduction for enrolled beneficiaries; if you have Extra Help and are paying more than the reduced copay, contact your plan or call 1-800-MEDICARE

Frequently Asked Questions